15
Participants
Start Date
April 7, 2025
Primary Completion Date
December 31, 2025
Study Completion Date
May 15, 2026
Plixorafenib
Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
Cobicistat 150 MG [Tybost]
Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
RECRUITING
Johns Hopkins, Baltimore
Collaborators (1)
Fore Biotherapeutics
INDUSTRY
Ivy Brain Tumor Foundation
UNKNOWN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER